Table of Contents 1 Report Overview 1.1 Study Scope 1.2 Key Market Segments 1.3 Players Covered: Ranking by Hormone Refractory Breast Cancer Revenue 1.4 Market Analysis by Type 1.4.1 Global Hormone Refractory Breast Cancer Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 Tumor Markers Therapy 1.4.3 Gene Expression Therapy 1.4.4 Gene Mutation Therapy 1.5 Market by Application 1.5.1 Global Hormone Refractory Breast Cancer Market Share by Application: 2020 VS 2026 1.5.2 Scientific Research and Production 1.5.3 Biological Science and Technology 1.5.4 Medical Technology 1.5.5 Medical Apparatus and Instruments 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends by Regions 2.1 Hormone Refractory Breast Cancer Market Perspective (2015-2026) 2.2 Hormone Refractory Breast Cancer Growth Trends by Regions 2.2.1 Hormone Refractory Breast Cancer Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Hormone Refractory Breast Cancer Historic Market Share by Regions (2015-2020) 2.2.3 Hormone Refractory Breast Cancer Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porter’s Five Forces Analysis 2.3.5 Hormone Refractory Breast Cancer Market Growth Strategy 2.3.6 Primary Interviews with Key Hormone Refractory Breast Cancer Players (Opinion Leaders) 3 Competition Landscape by Key Players 3.1 Global Top Hormone Refractory Breast Cancer Players by Market Size 3.1.1 Global Top Hormone Refractory Breast Cancer Players by Revenue (2015-2020) 3.1.2 Global Hormone Refractory Breast Cancer Revenue Market Share by Players (2015-2020) 3.1.3 Global Hormone Refractory Breast Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.2 Global Hormone Refractory Breast Cancer Market Concentration Ratio 3.2.1 Global Hormone Refractory Breast Cancer Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by Hormone Refractory Breast Cancer Revenue in 2019 3.3 Hormone Refractory Breast Cancer Key Players Head office and Area Served 3.4 Key Players Hormone Refractory Breast Cancer Product Solution and Service 3.5 Date of Enter into Hormone Refractory Breast Cancer Market 3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026) 4.1 Global Hormone Refractory Breast Cancer Historic Market Size by Type (2015-2020) 4.2 Global Hormone Refractory Breast Cancer Forecasted Market Size by Type (2021-2026) 5 Hormone Refractory Breast Cancer Breakdown Data by Application (2015-2026) 5.1 Global Hormone Refractory Breast Cancer Market Size by Application (2015-2020) 5.2 Global Hormone Refractory Breast Cancer Forecasted Market Size by Application (2021-2026) 6 North America 6.1 North America Hormone Refractory Breast Cancer Market Size (2015-2020) 6.2 Hormone Refractory Breast Cancer Key Players in North America (2019-2020) 6.3 North America Hormone Refractory Breast Cancer Market Size by Type (2015-2020) 6.4 North America Hormone Refractory Breast Cancer Market Size by Application (2015-2020) 7 Europe 7.1 Europe Hormone Refractory Breast Cancer Market Size (2015-2020) 7.2 Hormone Refractory Breast Cancer Key Players in Europe (2019-2020) 7.3 Europe Hormone Refractory Breast Cancer Market Size by Type (2015-2020) 7.4 Europe Hormone Refractory Breast Cancer Market Size by Application (2015-2020) 8 China 8.1 China Hormone Refractory Breast Cancer Market Size (2015-2020) 8.2 Hormone Refractory Breast Cancer Key Players in China (2019-2020) 8.3 China Hormone Refractory Breast Cancer Market Size by Type (2015-2020) 8.4 China Hormone Refractory Breast Cancer Market Size by Application (2015-2020) 9 Japan 9.1 Japan Hormone Refractory Breast Cancer Market Size (2015-2020) 9.2 Hormone Refractory Breast Cancer Key Players in Japan (2019-2020) 9.3 Japan Hormone Refractory Breast Cancer Market Size by Type (2015-2020) 9.4 Japan Hormone Refractory Breast Cancer Market Size by Application (2015-2020) 10 Southeast Asia 10.1 Southeast Asia Hormone Refractory Breast Cancer Market Size (2015-2020) 10.2 Hormone Refractory Breast Cancer Key Players in Southeast Asia (2019-2020) 10.3 Southeast Asia Hormone Refractory Breast Cancer Market Size by Type (2015-2020) 10.4 Southeast Asia Hormone Refractory Breast Cancer Market Size by Application (2015-2020) 11 India 11.1 India Hormone Refractory Breast Cancer Market Size (2015-2020) 11.2 Hormone Refractory Breast Cancer Key Players in India (2019-2020) 11.3 India Hormone Refractory Breast Cancer Market Size by Type (2015-2020) 11.4 India Hormone Refractory Breast Cancer Market Size by Application (2015-2020) 12 Central & South America 12.1 Central & South America Hormone Refractory Breast Cancer Market Size (2015-2020) 12.2 Hormone Refractory Breast Cancer Key Players in Central & South America (2019-2020) 12.3 Central & South America Hormone Refractory Breast Cancer Market Size by Type (2015-2020) 12.4 Central & South America Hormone Refractory Breast Cancer Market Size by Application (2015-2020) 13Key Players Profiles 13.1 AstraZeneca 13.1.1 AstraZeneca Company Details 13.1.2 AstraZeneca Business Overview and Its Total Revenue 13.1.3 AstraZeneca Hormone Refractory Breast Cancer Introduction 13.1.4 AstraZeneca Revenue in Hormone Refractory Breast Cancer Business (2015-2020)) 13.1.5 AstraZeneca Recent Development 13.2 AmpliMed Corporation 13.2.1 AmpliMed Corporation Company Details 13.2.2 AmpliMed Corporation Business Overview and Its Total Revenue 13.2.3 AmpliMed Corporation Hormone Refractory Breast Cancer Introduction 13.2.4 AmpliMed Corporation Revenue in Hormone Refractory Breast Cancer Business (2015-2020) 13.2.5 AmpliMed Corporation Recent Development 13.3 Roche 13.3.1 Roche Company Details 13.3.2 Roche Business Overview and Its Total Revenue 13.3.3 Roche Hormone Refractory Breast Cancer Introduction 13.3.4 Roche Revenue in Hormone Refractory Breast Cancer Business (2015-2020) 13.3.5 Roche Recent Development 13.4 Bluefish Pharmaceuticals AB 13.4.1 Bluefish Pharmaceuticals AB Company Details 13.4.2 Bluefish Pharmaceuticals AB Business Overview and Its Total Revenue 13.4.3 Bluefish Pharmaceuticals AB Hormone Refractory Breast Cancer Introduction 13.4.4 Bluefish Pharmaceuticals AB Revenue in Hormone Refractory Breast Cancer Business (2015-2020) 13.4.5 Bluefish Pharmaceuticals AB Recent Development 13.5 NeoCorp 13.5.1 NeoCorp Company Details 13.5.2 NeoCorp Business Overview and Its Total Revenue 13.5.3 NeoCorp Hormone Refractory Breast Cancer Introduction 13.5.4 NeoCorp Revenue in Hormone Refractory Breast Cancer Business (2015-2020) 13.5.5 NeoCorp Recent Development 13.6 Sanofi Genzyme 13.6.1 Sanofi Genzyme Company Details 13.6.2 Sanofi Genzyme Business Overview and Its Total Revenue 13.6.3 Sanofi Genzyme Hormone Refractory Breast Cancer Introduction 13.6.4 Sanofi Genzyme Revenue in Hormone Refractory Breast Cancer Business (2015-2020) 13.6.5 Sanofi Genzyme Recent Development 13.7 Neopharm 13.7.1 Neopharm Company Details 13.7.2 Neopharm Business Overview and Its Total Revenue 13.7.3 Neopharm Hormone Refractory Breast Cancer Introduction 13.7.4 Neopharm Revenue in Hormone Refractory Breast Cancer Business (2015-2020) 13.7.5 Neopharm Recent Development 13.8 Boehringer Ingelheim GmbH 13.8.1 Boehringer Ingelheim GmbH Company Details 13.8.2 Boehringer Ingelheim GmbH Business Overview and Its Total Revenue 13.8.3 Boehringer Ingelheim GmbH Hormone Refractory Breast Cancer Introduction 13.8.4 Boehringer Ingelheim GmbH Revenue in Hormone Refractory Breast Cancer Business (2015-2020) 13.8.5 Boehringer Ingelheim GmbH Recent Development 14Analyst's Viewpoints/Conclusions 15Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source 15.2 Disclaimer 15.3 Author Details

List of Tables Table 1. Hormone Refractory Breast Cancer Key Market Segments Table 2. Key Players Covered: Ranking by Hormone Refractory Breast Cancer Revenue Table 3. Ranking of Global Top Hormone Refractory Breast Cancer Manufacturers by Revenue (US$ Million) in 2019 Table 4. Global Hormone Refractory Breast Cancer Market Size Growth Rate by Type (US$ Million): 2020 VS 2026 Table 5. Key Players of Tumor Markers Therapy Table 6. Key Players of Gene Expression Therapy Table 7. Key Players of Gene Mutation Therapy Table 8. Global Hormone Refractory Breast Cancer Market Size Growth by Application (US$ Million): 2020 VS 2026 Table 9. Global Hormone Refractory Breast Cancer Market Size by Regions (US$ Million): 2020 VS 2026 Table 10. Global Hormone Refractory Breast Cancer Market Size by Regions (2015-2020) (US$ Million) Table 11. Global Hormone Refractory Breast Cancer Market Share by Regions (2015-2020) Table 12. Global Hormone Refractory Breast Cancer Forecasted Market Size by Regions (2021-2026) (US$ Million) Table 13. Global Hormone Refractory Breast Cancer Market Share by Regions (2021-2026) Table 14. Market Top Trends Table 15. Key Drivers: Impact Analysis Table 16. Key Challenges Table 17. Hormone Refractory Breast Cancer Market Growth Strategy Table 18. Main Points Interviewed from Key Hormone Refractory Breast Cancer Players Table 19. Global Hormone Refractory Breast Cancer Revenue by Players (2015-2020) (Million US$) Table 20. Global Hormone Refractory Breast Cancer Market Share by Players (2015-2020) Table 21. Global Top Hormone Refractory Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hormone Refractory Breast Cancer as of 2019) Table 22. Global Hormone Refractory Breast Cancer by Players Market Concentration Ratio (CR5 and HHI) Table 23. Key Players Headquarters and Area Served Table 24. Key Players Hormone Refractory Breast Cancer Product Solution and Service Table 25. Date of Enter into Hormone Refractory Breast Cancer Market Table 26. Mergers & Acquisitions, Expansion Plans Table 27. Global Hormone Refractory Breast Cancer Market Size by Type (2015-2020) (Million US$) Table 28. Global Hormone Refractory Breast Cancer Market Size Share by Type (2015-2020) Table 29. Global Hormone Refractory Breast Cancer Revenue Market Share by Type (2021-2026) Table 30. Global Hormone Refractory Breast Cancer Market Size Share by Application (2015-2020) Table 31. Global Hormone Refractory Breast Cancer Market Size by Application (2015-2020) (Million US$) Table 32. Global Hormone Refractory Breast Cancer Market Size Share by Application (2021-2026) Table 33. North America Key Players Hormone Refractory Breast Cancer Revenue (2019-2020) (Million US$) Table 34. North America Key Players Hormone Refractory Breast Cancer Market Share (2019-2020) Table 35. North America Hormone Refractory Breast Cancer Market Size by Type (2015-2020) (Million US$) Table 36. North America Hormone Refractory Breast Cancer Market Share by Type (2015-2020) Table 37. North America Hormone Refractory Breast Cancer Market Size by Application (2015-2020) (Million US$) Table 38. North America Hormone Refractory Breast Cancer Market Share by Application (2015-2020) Table 39. Europe Key Players Hormone Refractory Breast Cancer Revenue (2019-2020) (Million US$) Table 40. Europe Key Players Hormone Refractory Breast Cancer Market Share (2019-2020) Table 41. Europe Hormone Refractory Breast Cancer Market Size by Type (2015-2020) (Million US$) Table 42. Europe Hormone Refractory Breast Cancer Market Share by Type (2015-2020) Table 43. Europe Hormone Refractory Breast Cancer Market Size by Application (2015-2020) (Million US$) Table 44. Europe Hormone Refractory Breast Cancer Market Share by Application (2015-2020) Table 45. China Key Players Hormone Refractory Breast Cancer Revenue (2019-2020) (Million US$) Table 46. China Key Players Hormone Refractory Breast Cancer Market Share (2019-2020) Table 47. China Hormone Refractory Breast Cancer Market Size by Type (2015-2020) (Million US$) Table 48. China Hormone Refractory Breast Cancer Market Share by Type (2015-2020) Table 49. China Hormone Refractory Breast Cancer Market Size by Application (2015-2020) (Million US$) Table 50. China Hormone Refractory Breast Cancer Market Share by Application (2015-2020) Table 51. Japan Key Players Hormone Refractory Breast Cancer Revenue (2019-2020) (Million US$) Table 52. Japan Key Players Hormone Refractory Breast Cancer Market Share (2019-2020) Table 53. Japan Hormone Refractory Breast Cancer Market Size by Type (2015-2020) (Million US$) Table 54. Japan Hormone Refractory Breast Cancer Market Share by Type (2015-2020) Table 55. Japan Hormone Refractory Breast Cancer Market Size by Application (2015-2020) (Million US$) Table 56. Japan Hormone Refractory Breast Cancer Market Share by Application (2015-2020) Table 57. Southeast Asia Key Players Hormone Refractory Breast Cancer Revenue (2019-2020) (Million US$) Table 58. Southeast Asia Key Players Hormone Refractory Breast Cancer Market Share (2019-2020) Table 59. Southeast Asia Hormone Refractory Breast Cancer Market Size by Type (2015-2020) (Million US$) Table 60. Southeast Asia Hormone Refractory Breast Cancer Market Share by Type (2015-2020) Table 61. Southeast Asia Hormone Refractory Breast Cancer Market Size by Application (2015-2020) (Million US$) Table 62. Southeast Asia Hormone Refractory Breast Cancer Market Share by Application (2015-2020) Table 63. India Key Players Hormone Refractory Breast Cancer Revenue (2019-2020) (Million US$) Table 64. India Key Players Hormone Refractory Breast Cancer Market Share (2019-2020) Table 65. India Hormone Refractory Breast Cancer Market Size by Type (2015-2020) (Million US$) Table 66. India Hormone Refractory Breast Cancer Market Share by Type (2015-2020) Table 67. India Hormone Refractory Breast Cancer Market Size by Application (2015-2020) (Million US$) Table 68. India Hormone Refractory Breast Cancer Market Share by Application (2015-2020) Table 69. Central & South America Key Players Hormone Refractory Breast Cancer Revenue (2019-2020) (Million US$) Table 70. Central & South America Key Players Hormone Refractory Breast Cancer Market Share (2019-2020) Table 71. Central & South America Hormone Refractory Breast Cancer Market Size by Type (2015-2020) (Million US$) Table 72. Central & South America Hormone Refractory Breast Cancer Market Share by Type (2015-2020) Table 73. Central & South America Hormone Refractory Breast Cancer Market Size by Application (2015-2020) (Million US$) Table 74. Central & South America Hormone Refractory Breast Cancer Market Share by Application (2015-2020) Table 75. AstraZeneca Company Details Table 76. AstraZeneca Business Overview Table 77. AstraZeneca Product Table 78. AstraZeneca Revenue in Hormone Refractory Breast Cancer Business (2015-2020) (Million US$) Table 79. AstraZeneca Recent Development Table 80. AmpliMed Corporation Company Details Table 81. AmpliMed Corporation Business Overview Table 82. AmpliMed Corporation Product Table 83. AmpliMed Corporation Revenue in Hormone Refractory Breast Cancer Business (2015-2020) (Million US$) Table 84. AmpliMed Corporation Recent Development Table 85. Roche Company Details Table 86. Roche Business Overview Table 87. Roche Product Table 88. Roche Revenue in Hormone Refractory Breast Cancer Business (2015-2020) (Million US$) Table 89. Roche Recent Development Table 90. Bluefish Pharmaceuticals AB Company Details Table 91. Bluefish Pharmaceuticals AB Business Overview Table 92. Bluefish Pharmaceuticals AB Product Table 93. Bluefish Pharmaceuticals AB Revenue in Hormone Refractory Breast Cancer Business (2015-2020) (Million US$) Table 94. Bluefish Pharmaceuticals AB Recent Development Table 95. NeoCorp Company Details Table 96. NeoCorp Business Overview Table 97. NeoCorp Product Table 98. NeoCorp Revenue in Hormone Refractory Breast Cancer Business (2015-2020) (Million US$) Table 99. NeoCorp Recent Development Table 100. Sanofi Genzyme Company Details Table 101. Sanofi Genzyme Business Overview Table 102. Sanofi Genzyme Product Table 103. Sanofi Genzyme Revenue in Hormone Refractory Breast Cancer Business (2015-2020) (Million US$) Table 104. Sanofi Genzyme Recent Development Table 105. Neopharm Company Details Table 106. Neopharm Business Overview Table 107. Neopharm Product Table 108. Neopharm Revenue in Hormone Refractory Breast Cancer Business (2015-2020) (Million US$) Table 109. Neopharm Recent Development Table 110. Boehringer Ingelheim GmbH Business Overview Table 111. Boehringer Ingelheim GmbH Product Table 112. Boehringer Ingelheim GmbH Company Details Table 113. Boehringer Ingelheim GmbH Revenue in Hormone Refractory Breast Cancer Business (2015-2020) (Million US$) Table 114. Boehringer Ingelheim GmbH Recent Development Table 115. Research Programs/Design for This Report Table 116. Key Data Information from Secondary Sources Table 117. Key Data Information from Primary Sources List of Figures Figure 1. Global Hormone Refractory Breast Cancer Market Share by Type: 2020 VS 2026 Figure 2. Tumor Markers Therapy Features Figure 3. Gene Expression Therapy Features Figure 4. Gene Mutation Therapy Features Figure 5. Global Hormone Refractory Breast Cancer Market Share by Application: 2020 VS 2026 Figure 6. Scientific Research and Production Case Studies Figure 7. Biological Science and Technology Case Studies Figure 8. Medical Technology Case Studies Figure 9. Medical Apparatus and Instruments Case Studies Figure 10. Hormone Refractory Breast Cancer Report Years Considered Figure 11. Global Hormone Refractory Breast Cancer Market Size YoY Growth 2015-2026 (US$ Million) Figure 12. Global Hormone Refractory Breast Cancer Market Share by Regions: 2020 VS 2026 Figure 13. Global Hormone Refractory Breast Cancer Market Share by Regions (2021-2026) Figure 14. Porter's Five Forces Analysis Figure 15. Global Hormone Refractory Breast Cancer Market Share by Players in 2019 Figure 16. Global Top Hormone Refractory Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hormone Refractory Breast Cancer as of 2019 Figure 17. The Top 10 and 5 Players Market Share by Hormone Refractory Breast Cancer Revenue in 2019 Figure 18. North America Hormone Refractory Breast Cancer Market Size YoY Growth (2015-2020) (Million US$) Figure 19. Europe Hormone Refractory Breast Cancer Market Size YoY Growth (2015-2020) (Million US$) Figure 20. China Hormone Refractory Breast Cancer Market Size YoY Growth (2015-2020) (Million US$) Figure 21. Japan Hormone Refractory Breast Cancer Market Size YoY Growth (2015-2020) (Million US$) Figure 22. Southeast Asia Hormone Refractory Breast Cancer Market Size YoY Growth (2015-2020) (Million US$) Figure 23. India Hormone Refractory Breast Cancer Market Size YoY Growth (2015-2020) (Million US$) Figure 24. Central & South America Hormone Refractory Breast Cancer Market Size YoY Growth (2015-2020) (Million US$) Figure 25. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018 Figure 26. AstraZeneca Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2015-2020) Figure 27. AmpliMed Corporation Total Revenue (US$ Million): 2019 Compared with 2018 Figure 28. AmpliMed Corporation Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2015-2020) Figure 29. Roche Total Revenue (US$ Million): 2019 Compared with 2018 Figure 30. Roche Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2015-2020) Figure 31. Bluefish Pharmaceuticals AB Total Revenue (US$ Million): 2019 Compared with 2018 Figure 32. Bluefish Pharmaceuticals AB Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2015-2020) Figure 33. NeoCorp Total Revenue (US$ Million): 2019 Compared with 2018 Figure 34. NeoCorp Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2015-2020) Figure 35. Sanofi Genzyme Total Revenue (US$ Million): 2019 Compared with 2018 Figure 36. Sanofi Genzyme Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2015-2020) Figure 37. Neopharm Total Revenue (US$ Million): 2019 Compared with 2018 Figure 38. Neopharm Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2015-2020) Figure 39. Boehringer Ingelheim GmbH Total Revenue (US$ Million): 2019 Compared with 2018 Figure 40. Boehringer Ingelheim GmbH Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2015-2020) Figure 41. Bottom-up and Top-down Approaches for This Report Figure 42. Data Triangulation Figure 43. Key Executives Interviewed

AstraZeneca AmpliMed Corporation Roche Bluefish Pharmaceuticals AB NeoCorp Sanofi Genzyme Neopharm Boehringer Ingelheim GmbH